Skip to content
PubMed This is a summary of 68 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 68 referenced papers

Top Authors

Isabella C. Glitza Oliva
The University of Texas MD Anderson Cancer Center
Peter A. Forsyth
Moffitt Cancer Center
Sherise Desiree Ferguson
The University of Texas MD Anderson Cancer Center
Émilie Le Rhun
University of Zurich
Adrienne Ann Boire
Memorial Sloan Kettering Cancer Center
Michael A. Davies
The University of Texas MD Anderson Cancer Center
Inna Smalley
Moffitt Cancer Center
Michael Weller
University of Zurich
Ian E. McCutcheon
The University of Texas MD Anderson Cancer Center

Top Institutions

Ranked by publications Top 10 institutions

References

References (68)
  1. 1

    Therapy of leptomeningeal metastasis in solid tumors.

    Mack F, Baumert BG, Schäfer N, et al.

    Cancer treatment reviews 2016; (43()):83-91.

    PMID: 26827696
  2. 2

    Leptomeningeal carcinomatosis as primary manifestation of pancreatic cancer.

    Trinh VT, Medina-Flores R, Chohan MO

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2016; (30()):124-127 doi:10.1016/j.jocn.2015.12.027.

    PMID: 26972704
  3. 3

    Leptomeningeal metastases: a RANO proposal for response criteria.

    Chamberlain M, Junck L, Brandsma D, et al.

    Neuro-oncology 2017; (19(4)):484-492 doi:10.1093/neuonc/now183.

    PMID: 28039364
  4. 4

    Surgical Treatment for Leptomeningeal Disease.

    Volkov AA, Filis AK, Vrionis FD

    Cancer control : journal of the Moffitt Cancer Center 2017; (24(1)):47-53 doi:10.1177/107327481702400107.

    PMID: 28178712
  5. 5

    Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis.

    Boire A, Zou Y, Shieh J, et al.

    Cell 2017; (168(6)):1101-1113.e13 doi:10.1016/j.cell.2017.02.025.

    PMID: 28283064
  6. 6

    Cerebrospinal Fluid Dissemination and Neoplastic Meningitis in Primary Brain Tumors.

    Chowdhary S, Damlo S, Chamberlain MC

    Cancer control : journal of the Moffitt Cancer Center 2017; (24(1)):S1-S16 doi:10.1177/107327481702400118.

    PMID: 28557973
  7. 7

    Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.

    Lin X, Fleisher M, Rosenblum M, et al.

    Neuro-oncology 2017; (19(9)):1248-1254 doi:10.1093/neuonc/nox066.

    PMID: 28821205
  8. 8

    Leptomeningeal metastasis.

    Taillibert S, Chamberlain MC

    Handbook of clinical neurology 2018; (149()):169-204 doi:10.1016/B978-0-12-811161-1.00013-X.

    PMID: 29307353
  9. 9

    Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease.

    Ballester LY, Glitza Oliva IC, Douse DY, et al.

    Journal of neuropathology and experimental neurology 2018; (77(7)):628-635 doi:10.1093/jnen/nly046.

    PMID: 29873738
  10. 10

    The Comparative Treatment of Intraventricular Chemotherapy by Ommaya Reservoir vs. Lumbar Puncture in Patients With Leptomeningeal Carcinomatosis.

    Montes de Oca Delgado M, Cacho Díaz B, Santos Zambrano J, et al.

    Frontiers in oncology 2018; (8()):509 doi:10.3389/fonc.2018.00509.

    PMID: 30524956
  11. 11

    Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study.

    Mitsuya K, Nakasu Y, Hayashi N, et al.

    PloS one 2019; (14(1)):e0210074 doi:10.1371/journal.pone.0210074.

    PMID: 30629621
  12. 12

    Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

    Ferguson SD, Bindal S, Bassett RL, et al.

    Journal of neuro-oncology 2019; (142(3)):499-509 doi:10.1007/s11060-019-03121-2.

    PMID: 30847840
  13. 13

    Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis.

    Kim HS, Park JB, Gwak HS, et al.

    World journal of surgical oncology 2019; (17(1)):59 doi:10.1186/s12957-019-1595-7.

    PMID: 30917830
  14. 14

    How we treat patients with leptomeningeal metastases.

    Le Rhun E, Preusser M, van den Bent M, et al.

    ESMO open 2019; (4(Suppl 2)):e000507 doi:10.1136/esmoopen-2019-000507.

    PMID: 31231573
  15. 15

    Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions.

    Glitza IC, Smalley KSM, Brastianos PK, et al.

    Pigment cell & melanoma research 2020; (33(4)):527-541 doi:10.1111/pcmr.12861.

    PMID: 31916400
  16. 16

    Melanoma brain metastases - Interdisciplinary management recommendations 2020.

    Gutzmer R, Vordermark D, Hassel JC, et al.

    Cancer treatment reviews 2020; (89()):102083 doi:10.1016/j.ctrv.2020.102083.

    PMID: 32736188
  17. 17

    An overview of leptomeningeal disease.

    Nguyen TK, Nguyen EK, Soliman H

    Annals of palliative medicine 2021; (10(1)):909-922 doi:10.21037/apm-20-973.

    PMID: 32921068
  18. 18

    Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases.

    Tétu P, Sirven-Villaros L, Cuzzubbo S, et al.

    Cancers 2020; (12(9)) doi:10.3390/cancers12092635.

    PMID: 32947841
  19. 19

    Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.

    Le Rhun E, Devos P, Weller J, et al.

    Neuro-oncology 2021; (23(7)):1100-1112 doi:10.1093/neuonc/noaa298.

    PMID: 33367859
  20. 20

    Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.

    Chorti E, Kebir S, Ahmed MS, et al.

    European journal of cancer (Oxford, England : 1990) 2021; (148()):395-404 doi:10.1016/j.ejca.2021.02.016.

    PMID: 33789203
  21. 21

    Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid.

    White MD, Klein RH, Shaw B, et al.

    JAMA network open 2021; (4(8)):e2120040 doi:10.1001/jamanetworkopen.2021.20040.

    PMID: 34369989
  22. 22

    Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes.

    Bander ED, Yuan M, Reiner AS, et al.

    Journal of neuro-oncology 2021; (154(3)):301-313 doi:10.1007/s11060-021-03827-2.

    PMID: 34406564
  23. 23

    Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.

    Brastianos PK, Strickland MR, Lee EQ, et al.

    Nature communications 2021; (12(1)):5954 doi:10.1038/s41467-021-25859-y.

    PMID: 34642329
  24. 24

    CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease.

    Najem H, Marisetty A, Horbinski C, et al.

    Frontiers in immunology 2021; (12()):745893 doi:10.3389/fimmu.2021.745893.

    PMID: 34691054
  25. 25

    Leptomeningeal Carcinomatosis: A Call for Optimizing Diagnostic Sensitivity by the Hematology Laboratory.

    Lardinois B, Miller L, Randazzo A, et al.

    Case reports in oncology 2021; (14(2)):1248-1253 doi:10.1159/000518314.

    PMID: 34703443
  26. 26

    Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.

    Piña Y, Yadugiri S, Yeboa DN, et al.

    Current oncology reports 2022; (24(1)):43-54 doi:10.1007/s11912-021-01162-3.

    PMID: 35059999
  27. 27

    Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases.

    Lowe SR, Wang CP, Brisco A, et al.

    Neuro-oncology 2022; (24(8)):1307-1317 doi:10.1093/neuonc/noac023.

    PMID: 35092434
  28. 28

    Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments.

    Ozcan G, Singh M, Vredenburgh JJ

    Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(1)):11-29 doi:10.1158/1078-0432.CCR-22-1585.

    PMID: 35972437
  29. 29

    Case Report: Focal leptomeningeal disease, atypical cancer of unknown primary site.

    Vences MA, Araujo-Chumacero MM, Urrunaga-Pastor D, et al.

    F1000Research 2022; (11()):885 doi:10.12688/f1000research.122434.2.

    PMID: 36188732
  30. 30

    Diagnostic accuracy of cerebrospinal fluid liquid biopsy and MRI for leptomeningeal metastases in solid cancers: A systematic review and meta-analysis.

    Nakasu Y, Deguchi S, Nakasu S, et al.

    Neuro-oncology advances 2023; (5(1)):vdad002 doi:10.1093/noajnl/vdad002.

    PMID: 36968290
  31. 31

    Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases.

    Khaled ML, Tarhini AA, Forsyth PA, et al.

    Cancers 2023; (15(6)) doi:10.3390/cancers15061884.

    PMID: 36980770
  32. 32

    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.

    Glitza Oliva IC, Ferguson SD, Bassett R, et al.

    Nature medicine 2023; (29(4)):898-905 doi:10.1038/s41591-022-02170-x.

    PMID: 36997799
  33. 33

    [Spinal metastases combined with leptomeningeal metastasis: A case report].

    Ma LJ, Hu PP, Liu XG

    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2023; (55(3)):563-566.

    PMID: 37291936
  34. 34

    Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.

    Steininger J, Gellrich FF, Engellandt K, et al.

    International journal of molecular sciences 2023; (24(14)) doi:10.3390/ijms241411443.

    PMID: 37511202
  35. 35

    Survival and quality of life after CSF diversion in adult patients with leptomeningeal metastasis-associated hydrocephalus: a systematic review and meta-analysis.

    Dhaliwal J, Ruiz-Perez M, Mihaela-Vasilica A, et al.

    Neurosurgical focus 2023; (55(2)):E16 doi:10.3171/2023.5.FOCUS23195.

    PMID: 37527677
  36. 36

    Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.

    Smalley I, Boire A, Brastianos P, et al.

    Pigment cell & melanoma research 2024; (37(1)):51-67 doi:10.1111/pcmr.13116.

    PMID: 37622466
  37. 37

    Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.

    Sherman WJ, Romiti E, Michaelides L, et al.

    Current treatment options in oncology 2023; (24(12)):1962-1977 doi:10.1007/s11864-023-01155-3.

    PMID: 38158477
  38. 38

    Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease.

    Alhaddad H, Ospina OE, Khaled ML, et al.

    bioRxiv : the preprint server for biology 2023; doi:10.1101/2023.12.18.572266.

    PMID: 38187574
  39. 39

    Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSideTM.

    Puri S, Malani R, Chalmers A, et al.

    Neuro-oncology advances 2024; (6(1)):vdad150 doi:10.1093/noajnl/vdad150.

    PMID: 38196737
  40. 40

    Ventriculoperitoneal shunting with an on-off valve for patients with leptomeningeal metastases and intracranial hypertension.

    Huntoon KM, Gasco J, Glitza Oliva IC, et al.

    Neuro-oncology practice 2024; (11(1)):56-63 doi:10.1093/nop/npad056.

    PMID: 38222058
  41. 41

    Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.

    Sener U, Webb M, Breen WG, et al.

    Journal of immunotherapy and precision oncology 2024; (7(1)):1-6 doi:10.36401/JIPO-23-20.

    PMID: 38327758
  42. 42

    Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors.

    Barbour AB, Kotecha R, Lazarev S, et al.

    Advances in radiation oncology 2024; (9(2)):101377 doi:10.1016/j.adro.2023.101377.

    PMID: 38405313
  43. 43

    Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.

    Barbour AB, Blouw B, Taylor LP, et al.

    Journal of neuro-oncology 2024; (167(3)):509-514 doi:10.1007/s11060-024-04615-4.

    PMID: 38441840
  44. 44

    The anatomic basis of leptomeningeal metastasis.

    Freret ME, Boire A

    The Journal of experimental medicine 2024; (221(4)) doi:10.1084/jem.20212121.

    PMID: 38451255
  45. 45

    Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease.

    Law V, Smalley I, Evernden BR, et al.

    Journal of visualized experiments : JoVE 2024; doi:10.3791/66071.

    PMID: 38619274
  46. 46

    Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.

    Wilcox JA, Chukwueke UN, Ahn MJ, et al.

    Neuro-oncology 2024; (26(10)):1781-1804 doi:10.1093/neuonc/noae103.

    PMID: 38902944
  47. 47

    Detection of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series.

    Dirven I, Vounckx M, Kessels JI, et al.

    Pigment cell & melanoma research 2024; (37(6)):822-830 doi:10.1111/pcmr.13186.

    PMID: 38990845
  48. 48

    Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.

    Saberian C, Milton DR, Simon J, et al.

    Neuro-oncology practice 2024; (11(4)):452-463 doi:10.1093/nop/npae026.

    PMID: 39006528
  49. 49

    NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases.

    Le Rhun E, Nayak L, Lim-Fat MJ, et al.

    Neuro-oncology 2025; (27(2)):455-465 doi:10.1093/neuonc/noae171.

    PMID: 39208403
  50. 50

    A Rare Cause of Cauda Equina Syndrome: Neuroendocrine Carcinoma of the Lung.

    Ford PH, Carbo E, Rennie A, Virgilio R

    Cureus 2024; (16(9)):e69263 doi:10.7759/cureus.69263.

    PMID: 39282491
  51. 51

    Leptomeningeal Disease Secondary to Invasive Ductal Carcinoma of the Breast: A Rapidly Progressive and Fatal Complication.

    Dhawan S, Mattathil F, Malik I, et al.

    Cureus 2024; (16(11)):e74421 doi:10.7759/cureus.74421.

    PMID: 39600551
  52. 52

    Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).

    Pedersen S, Johansen EL, Højholt KL, et al.

    European journal of cancer (Oxford, England : 1990) 2025; (217()):115253 doi:10.1016/j.ejca.2025.115253.

    PMID: 39874911
  53. 53

    Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.

    Long GV, Atkinson V, Lo SN, et al.

    The Lancet. Oncology 2025; (26(3)):320-330 doi:10.1016/S1470-2045(24)00735-6.

    PMID: 39978375
  54. 54

    Lumboperitoneal and ventriculoperitoneal shunting for leptomeningeal disease-associated hydrocephalus: a systematic review and meta-analysis of postoperative outcomes and comparative effectiveness.

    Hajikarimloo B, Mohammadzadeh I, Tos SM, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(10)):4899-4912 doi:10.1007/s10072-025-08321-5.

    PMID: 40550976
  55. 55

    Long-term survival in a patient with brain metastases and leptomeningeal disease of breast cancer: a case report of a patient receiving trastuzumab-deruxtecan.

    von Kroge P, Müller V, Schmalfeldt B, et al.

    Archives of gynecology and obstetrics 2025; (312(5)):1821-1827 doi:10.1007/s00404-025-08096-2.

    PMID: 40627061
  56. 56

    Continuous Intrathecal Infusion of Nivolumab in Advanced Melanoma With Concomitant Leptomeningeal Disease: Efficacy, Safety, and Pharmacokinetics.

    Faillot M, Goldwirt L, Jouenne F, et al.

    Neurosurgery 2026; (99(4)):882-889 doi:10.1227/neu.0000000000003924.

    PMID: 41636506
  57. 57

    Pathophysiology and treatment of leptomeningeal metastases in lung cancer.

    Hida T

    Translational lung cancer research 2026; (15(1)):19 doi:10.21037/tlcr-2025-aw-1247.

    PMID: 41659263
  58. 58

    Cerebrospinal Fluid Shunting in Hydrocephalus Secondary to Leptomeningeal Metastases: A Systematic Review and Meta-Analysis of Functional Outcomes, Symptom Improvement, and Complications.

    Alomari O, Uslu I, Kılıç D, et al.

    World neurosurgery 2026; (209()):124901 doi:10.1016/j.wneu.2026.124901.

    PMID: 41796675
  59. 59

    Melanoma leptomeningeal disease: Advances in diagnosis and emerging therapeutic strategies.

    Middleton ML, Lucke-Wold B

    World journal of experimental medicine 2026; (16(1)):117938 doi:10.5493/wjem.v16.i1.117938.

    PMID: 41883443
  60. 60

    Utility of cerebrospinal fluid circulating tumor cell quantification and next-generation sequencing in patients with suspicion for leptomeningeal disease.

    Onoichenco A, Galvez R, Schultz A, et al.

    Neuro-oncology advances 2026; (8(1)):vdag046 doi:10.1093/noajnl/vdag046.

    PMID: 41924095
  61. 61

    Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study.

    Aboelatta MA, Rezazadeh A, Sener U, et al.

    Melanoma research 2026; (36(3)):203-210 doi:10.1097/CMR.0000000000001088.

    PMID: 42053986
  62. 62

    Decision-Making in Intrathecal Therapy for Leptomeningeal Disease.

    Weindler S, Hundsberger T, Addeo A, et al.

    Oncology 2026; (104(10)):1203-1214 doi:10.1159/000552332.

    PMID: 42166400
  63. 63

    Lumbar-ventricular cerebrospinal fluid pressure discrepancy in leptomeningeal metastasis associated intracranial hypertension.

    Chang KW, Jeon WJ, Lee WJ, et al.

    Fluids and barriers of the CNS 2026; (23(1)).

    PMID: 42218510
  64. 64

    H3K27M-Mutant Diffuse Leptomeningeal Glioneuronal Tumor Presenting as Communicating Hydrocephalus: Case Report and Literature Review.

    Narendrakumar A, Mishra S, Kumar A, et al.

    Pediatric neurosurgery 2026; 1 doi:10.1159/pne/aeiag003.

    PMID: 42599848
  65. 65

    Survival and hematologic toxicity after whole-brain radiotherapy, photon craniospinal irradiation, and proton craniospinal irradiation for solid-tumor leptomeningeal disease: a systematic review.

    Munir M, Sehrawat K, Hassan H, et al.

    Journal of neuro-oncology 2026; (179(2)).

    PMID: 42667527
  66. 66

    Spinal leptomeningeal disease in patients with solid tumors: A single-center study on clinical presentation, diagnosis, treatment, and outcomes.

    Shaked Z, Eitner C, Jelgersma C, et al.

    Brain & spine 2026; (6()):106660 doi:10.1016/j.bas.2026.106660.

    PMID: 42825100
  67. 67

    Multi-omics liquid biopsy for leptomeningeal metastases in lung cancer: from molecular mechanisms to precision diagnosis and treatment.

    Zhang R, Zhao Q, Cao Y, et al.

    Lung cancer (Amsterdam, Netherlands) 2026; (222()):109667 doi:10.1016/j.lungcan.2026.109667.

    PMID: 42893629
  68. 68

    Carcinomatous meningitis: Current insights into diagnosis, prognosis and management.

    Gambaretti M, Lavalley A, Ollivier M, et al.

    La Revue de medecine interne 2026; doi:10.1016/j.revmed.2026.09.016.

    PMID: 42907241